	US 12,122,806 B2
	Adenoviral coat protein derived delivery vehicles
Imre Berger, Clifton Bristol (GB); Frédéric Garzoni, Rives (FR); and Pascal Fender, Grenoble (FR)
Assigned to THE EUROPEAN MOLECULAR BIOLOGY LABORATORY, Heidelberg (DE); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR)
Filed by THE EUROPEAN MOLECULAR BIOLOGY LABORATORY, Heidelberg (DE); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR)
Filed on Feb. 1, 2022, as Appl. No. 17/590,444.
Application 17/590,444 is a division of application No. 16/088,905, granted, now 11,274,127, previously published as PCT/EP2017/057747, filed on Mar. 31, 2017.
Claims priority of application No. 16163372 (EP), filed on Mar. 31, 2016.
Prior Publication US 2022/0162267 A1, May 26, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01)

CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); C12N 7/00 (2013.01); C12N 2710/10322 (2013.01); C12N 2710/10323 (2013.01); C12N 2710/10334 (2013.01)]

39 Claims

1. A virus-like particle (VLP) comprising 12 pentamers each comprising five adenovirus penton base protomers and at least one engineered polypeptide comprising at least one adenovirus fibre protein N-terminal fragment specifically binding to an adenovirus fibre protein binding cleft of a penton base protomer and:

(i) a non-adenoviral peptide, optionally linked to the fibre protein fragment via peptide linker, and/or

(ii) a drug or label that is covalently or non-covalently coupled to said adenovirus fibre protein N-terminal fragment.